References
- Wang C. Pulmonary thromboembolism. In Textbook of Internal Medicine, Lu ZY, Zhong NS (editors). seventh ed., Beijing: People's Medical Publishing House, 2008: p. 79–87.
- Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353 (9162): 1386–9.
- Kroegel C, Reissig A. Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. Respiration 2003; 70(1): 7–30.
- Anderson F, Spencer F. Risk factors for venous thromboembolism. Circulation 2003; 107 (23 Suppl 1):9–16.
- Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 2010; 341: 4245.
- Zornberg GL, Jick H. Antipsychotic drug use and risk of firsttime idiopathic venous thromboembolism: a case-control study. Lancet 2000; 356 (9237): 1219–23.
- Waage IM, Gedde-Dahl A. Pulmonary embolism possibly associated with olanzapine treatment. BMJ 2003; 327(7428): 1384.
- Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005; 165(22): 2677–82.
- Burrows GD, Kremer CM. Mirtazapine: Clinical advantages in the treatment of depression. J Clin Psychopharmacol 1997; 17(2): 34–9.
- Remeron [package insert]. Nanjing, China: Organon; 2006.
- Barbuto J. Preventing sudden death during a catatonic episode. Hosp Community Psychiatry 1983; 34(1): 72–3.
- Kallner G, Lindelius R, Petterson U, Stockman O, Tham A. Mortalityin 497 patients with affective disorders attending a lithium clinic or after having left it. Pharmacopsychiatry 2000; 33(1): 8–13.
- Thomassen R, Vandenbrouke JP, Rosendaal FR. Antipsychotic medications and venous thromboembolism. Br J Psychiatry 2001; 179: 63–6.
- Parkin L, Skegg DC, Herbison GP, Paul C. Psychotic drugs and fatal pulmonary embolism. Pharmacoepidemiol Drug Saf 2003; 12(8): 647–52.
- Lacut K, Le Gal G, Couturaud F, Cornily G, Leroyer C, Mottier D, et al. Association between antipsychotic drugs, antidepressant drugs and venousthromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol 2007; 21(6): 643–50.
- Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Thromb Haemost 2002; 88(2): 205–9.
- Jick SS, Li L. Antidepressant use and risk of venous thromboembolism. Pharmacotherapy 2008; 28(2): 144–50.
- Arnone D, Hansen L, Davies G. Pulmonary embolism and severe depression. Am J Psychiatry 2002; 159(5): 873–4.
- Kurne A, Ertugrul A, Anil Yagcioglu AE, Yazici KM. Venous thromboembolism and escitalopram. Gen Hosp Psychiatry. 2004; 26(6): 481–3.
- Ginsberg DL. Mirtazapine-risperidone combination associated with pulmonary thromboembolism and rhabdomyolysis. Prim Psychiatry 2006; 13(7): 25–6.
- DWH Tam. Sudden Death from Pulmonary Hypertension in a Depressed Patient: a Case Report. Hong Kong J Psychiatry 2009; 19: 155–8.
- Brandstetter RD, Gotz VP. Recurrence of intravenous-diazepam- inducedphlebitis from oral diazepam. Drug Intell Clin Pharm 1983; 17(2): 125–6.
- Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998; 51(3): 215–35.
- Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37(1): 12–6.